To amend the Commodity Exchange Act to prohibit the listing of contracts relating to war, death, and similar activities.

HR7942, titled the "Discouraging Exploitative Assassination, Tragedy, and Harm Betting in Event Trading Systems Act" or the "DEATH BETS Act," was introduced in the House on March 16, 2026, and immediately referred to the House Committee on Agriculture. This bill proposes to amend the Commodity Exchange Act to prohibit registered entities from listing or clearing agreements, contracts, transactions, or swaps based on excluded commodities that involve, relate to, or reference terrorism, assassination, war, or an individual's death. A companion bill, S4035, has also been introduced in the Senate and referred to the Committee on Agriculture, Nutrition, and Forestry, indicating a coordinated legislative effort. This bill does not involve direct funding or appropriations. Instead, its mechanism is regulatory, imposing a prohibition on certain types of derivatives contracts. The financial impact would be a restriction on potential revenue growth for derivatives exchanges by preventing them from entering or expanding into this specific market segment. There is no money trail in terms of government spending; rather, it is a regulatory constraint on market activity. The primary structural losers are companies operating derivatives exchanges, specifically $CME (CME Group Inc.) and $ICE (Intercontinental Exchange, Inc.), as these entities would be directly prohibited from offering these types of contracts. While the specific revenue generated from these 'war, death, and similar activities' contracts is not provided, the bill text indicates they are a new, high-growth area, suggesting a potential loss of future revenue diversification. The bill's early stage means no immediate financial impact, but it signals a potential future regulatory headwind for these companies. Looking at recent market data, $CME is currently at $308.57, up +3.69% over the last 7 days but down -2.6% over the last 30 days. $ICE is currently at $166.39, up +6.02% over the last 7 days and +1.46% over the last 30 days. The recent positive 7-day performance for both tickers suggests the market is not yet pricing in significant impact from this early-stage bill. The legislative path ahead involves committee consideration in both the House and Senate, followed by potential floor votes and reconciliation if passed by both chambers. Given the early stage, passage is not guaranteed, but the existence of companion bills suggests some legislative momentum.